您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Cyclophosphamide
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Cyclophosphamide
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Cyclophosphamide图片
包装与价格:
包装价格(元)
100mg电议
200mg电议
500mg电议
5g电议

产品介绍
环磷酰胺是一种合成烷化剂,化学性质与氮芥有关,具有抗肿瘤活性,是一种免疫抑制剂。

Cell lines

Multiple Myeloma cell line (MM1.S)

Preparation Method

MM1.S cells were treated with low dose concentrations of cyclophosphamide over a 48 hour time course, after which in vitro cell death was quantified by flow cytometry.

Reaction Conditions

2.5, 5, 10, 20μM Cyclophosphamide for 48h.

Applications

Low-dose cyclophosphamide treatment increased MM cell death in a dose-dependent manner, inducing moderate levels of cell death at 20μM cyclophosphamide after 24 hours and from 10μM cyclophosphamide after 48 hours.

Animal models

C57BL/6 mice

Preparation Method

C57BL/6 mice were subcutaneously injected with B16F10 cells and daily treated in a low-dose Cyclophosphamide, Paclitaxel and Docetaxel Animals were monitored every 3 days for tumor growth.

Dosage form

10 mg/kg Cyclophosphamide, intraperitoneal(i.p.) injection

Applications

Cyclophosphamide chemotherapy significantly delays tumor growth as compared to the control group. At day 19, when all animals in both experimental groups were still alive and comparable, mice treated with metronomic chemotherapy showed a 70% reduction in tumor dimension.Such effect was directly correlated with reduction of CD4+ Tcells and parallel increase of CD8+ Tcells

产品描述

Cyclophosphamide is a frequently used chemotherapy, often in combination with other chemotherapy types, for the treatment of breast cancer, malignant lymphomas, multiple myeloma, and neuroblastoma[1].

Cyclophosphamide’s immunomodulatory function was investigated by conditioning macrophages with tumor cell secretome collected from cyclophosphamide treated MM cell lines. CTX-TCS conditioning augmented the migratory capacity of macrophages and increased CD32 and CD64 Fcγ receptor expression on their cell surface. Daratumumab-specific tumor clearance was increased by conditioning macrophages with CTX-TCS in a dose-dependent manner[2]

In vivo,Cyclophosphamide induces early nonapoptotic death of superficial cells, followed by apoptotic death of deeper layers. H&E staining was performed over several days to determine the global urothelial injury and regeneration pattern after cyclophosphamide injection. Compared with uninjured mice, significant sloughing of urothelial cell layers as well as submucosal hemorrhage and inflammation were observed 1 day after cyclophosphamide. cyclophosphamide induces nonapoptotic death of superficial cells starting at 2 hours, followed by apoptotic loss of intermediate and basal cells starting at 4 hours[3]

References:
[1]. Gernaat SAM, von Stedingk H, et al. Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard-hemoglobin in breast cancer patients: The TailorDose I study. Sci Rep. 2021 Feb 1;11(1):2707.
[2]. Naicker SD, Feerick CL, et al. Cyclophosphamide alters the tumor cell secretome to potentiate the anti-myeloma activity of daratumumab through augmentation of macrophage-mediated antibody dependent cellular phagocytosis. Oncoimmunology. 2021 Jan 25;10(1):1859263.
[3]. Narla ST, Bushnell DS, et al. Keratinocyte Growth Factor Reduces Injury and Leads to Early Recovery from Cyclophosphamide Bladder Injury. Am J Pathol. 2020 Jan;190(1):108-124.